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Abstract
Idiopathic chronic eosinophilic pneumonia (ICEP) is characterized by subacute or chronic
respiratory and general symptoms, alveolar and/or blood eosinophilia, and peripheral pulmonary
infiltrates on chest imaging. Eosinophilia is present in most cases, usually in excess of 1000/mm3. In
absence of significant blood eosinophilia, a diagnosis of ICEP is supported by the demonstration of
bronchoalveolar lavage eosinophilia. ICEP is typically associated with eosinophil counts higher than
lymphocyte counts in the bronchoalveolar lavage. ICEP is a rare disorder of unknown cause. Its
exact prevalence remains unknown. ICEP may affect every age group but is rare in childhood. It is
twice as frequent in women as in men. One third to one half of the ICEP patients have a history of
asthma. The mainstay of treatment of ICEP is systemic corticosteroids. Response to oral
corticosteroid therapy is dramatic and has led to the consideration of corticosteroid challenge as
a diagnostic test for ICEP. Nevertheless, relapses or development of severe asthma are frequent
when tapering or withdrawing treatment. Long-term oral corticosteroid therapy is necessary in up
to half of the patients.
Disease name and synonyms
Idiopathic chronic eosinophilic pneumonia (ICEP);
Chronic eosinophilic pneumonia (CEP);
Carrington's disease.
Diagnosis criteria/definition
Idiopathic chronic eosinophilic pneumonia (ICEP) is a
rare disorder of unknown cause characterized by subacute
or chronic respiratory and general symptoms, alveolar
and/or blood eosinophilia, and peripheral pulmonary
infiltrates on chest imaging. There are no strict diagnostic
criteria for ICEP. Diagnosis is usually based on the associ-
ation of:
1) respiratory symptoms of usually more than 2 weeks
duration;
2) alveolar and/or blood eosinophilia (alveolar eosi-
nophilia ≥ 40% at bronchoalveolar lavage (BAL) differen-
tial cell count; blood eosinophilia ≥ 1000/mm3);
3) pulmonary infiltrates with usually a peripheral pre-
dominance on chest imaging;
4) exclusion of any known cause of eosinophilic lung dis-
ease.
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Epidemiology
ICEP is a rare disorder. Its exact prevalence remains
unknown. ICEP has been reported to contribute to 0–
2.5% of cases included in different registries of interstitial
lung diseases [1].
ICEP may affect every age group but is extremely rare in
childhood [2-5]. It is twice as frequent in women as in
men [2,3,6,7].
One third to one half of the ICEP patients have a history
of asthma [7-12]; less than 10% are active smokers [2,3,7].
It has recently been reported that ICEP may be primed by
radiation therapy for breast cancer [13].
Clinical description
Symptoms are non-specific and usually include respira-
tory and general symptoms, which are either subacute or
chronic. Accordingly, the symptoms are most often
present for about a month before diagnosis is made.
Respiratory signs
Dyspnea and cough are always present. The severity of
dyspnea is highly variable [3]. Respiratory failure necessi-
tating mechanical ventilation, however, is very rare
[14,15], in contrast with idiopathic acute eosinophilic
pneumonia. Wheezing occurs in about half of the cases.
Chest auscultation findings are non-specific, with possi-
ble inspiratory crackles or expiratory wheezes [3].
General manifestations
Asthenia, weight loss (sometimes marked), and nocturnal
sweat or fever are frequent [2,3,7].
Extrathoracic manifestations
Extrathoracic features are absent in ICEP. When the symp-
toms and signs of extra-pulmonary involvement are
present, a diagnosis of Churg-Strauss syndrome (CSS) or
idiopathic hypereosinophilic syndrome (IHS) should be
considered. A few patients with an initial diagnosis of
ICEP, however, may develop minor extrathoracic mani-
festations without further fulfilling the diagnostic criteria
for either CSS or IHS. It is noteworthy that a continuum
between ICEP and CSS has been suggested [16-18].
Paraclinical findings/diagnostic studies
Chest imaging
ICEP is characterized by peripheral parenchymal infil-
trates on chest imaging. These infiltrates can be either uni-
lateral or most often bilateral. The most distinctive chest
X-ray images mimic the photographic negative of acute
pulmonary edema [10]. This typical pattern, however, is
absent in the majority of cases of ICEP [2] and is not spe-
cific for the disorder, since it has also been described in
cryptogenic organizing pneumonia, sarcoidosis, or drug-
induced pneumonia. The parenchymal infiltrates are alve-
olar in nature, ranging from ground-glass opacities to con-
solidation with air bronchogram. They are sometimes
migratory [3,7]. Pleural effusion is uncommon.
Computing tomography (CT) may show discrete ground-
glass opacities that are not discernible on X-rays. Bilateral
parenchymal abnormalities are commonly seen with CT
[3]. Mediastinal lymph node enlargement has been
described [3,19].
Laboratory findings
Although anecdotal cases without blood eosinophilia
have been reported [2,9,20], it is present in most cases,
usually in excess of 1000/mm3 [3]. In the absence of sig-
nificant blood eosinophilia, a diagnosis of ICEP is sup-
ported by the demonstration of bronchoalveolar lavage
eosinophilia (≥ 40%). Erythrocyte sedimentation rate and
C-reactive protein level are usually increased. Total immu-
noglobulin E (IgE) levels are elevated in about half of the
cases [3], reflecting the high proportion of patients with
an atopic background.
Bronchoalveolar lavage
Bronchoalveolar lavage in ICEP always reveals abnor-
mally high levels of eosinophils, representing 12% to
95% (mean: 58%) of the total cell count [3]. In contrast
to cryptogenic organizing pneumonia with which it shares
many common features, ICEP is typically associated with
eosinophil counts higher than lymphocyte counts in BAL.
Pulmonary function tests
ICEP can be associated with either a restrictive or an
obstructive pattern on pulmonary function tests. The lat-
ter pattern is more often present in patients with a history
of asthma [2,16]. However, spirometry remains within
normal limits in up to one third of the cases [3]. Diffusion
tests often show a reduced carbon monoxide (CO) trans-
fer factor (DLCO); the CO transfer coefficient (KCO) is
reduced in up to one quarter of the patients with ICEP [3].
Arterial blood gases usually demonstrate a mild to moder-
ate hypoxemia [2,9,16].
Pathological findings
Pathological confirmation of ICEP is usually not neces-
sary to establish the diagnosis. When performed, lung
biopsy shows an interstitial and alveolar inflammation
with a clear-cut predominance of eosinophils [2,9]. Infil-
tration of pulmonary vessels with eosinophils may be
observed but necrotising or granulomatous vasculitis are
not present in ICEP [6]. Foci of organising pneumonia are
frequently observed [2].Orphanet Journal of Rare Diseases 2006, 1:11 http://www.OJRD.com/content/1/1/11
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Differential diagnosis
Eosinophilic lung diseases of known cause
Several drugs may cause eosinophilic pneumonias. The
most frequently involved drugs are nonsteroidal anti-
inflammatory agents, including salicylates used in inflam-
matory bowel diseases (e.g. sulfasalazine) and antibiotics,
including minocycline and cotrimoxazole. A detailed his-
tory with respect to drugs consumption is needed in order
to exclude any potential pharmacological cause of eosi-
nophilic pneumonia. Updated information on causative
drugs is available [21,22].
Allergic broncho-pulmonary aspergillosis (ABPA) and
other allergic broncho-pulmonary mycoses are character-
ized by type I and III immune reactions against Aspergillus
fumigatus or other fungi. Characteristic features of ABPA
are asthma, migratory pulmonary infiltrates associated
with blood and alveolar eosinophilia, central bron-
chiectasis, high total IgE levels, positive immediate and
late skin tests in response to the causative agent, as well as
positive specific IgE and precipitins [23].
Some parasitic infections that are generally transient are
associated with eosinophilia and pulmonary infiltrates.
Causative agents are Ascaris lumbricoides,  Toxocara
canis,Taenia saginata, Trichinella spiralis and Fasciola hepat-
ica. For patients living in tropical areas or with a history of
travel in tropical areas, other parasites must be included in
the search: Strongyloides stercoralis,  Wuchereria bancrofti,
Brugia malayi, Schistosoma mansoni and Schistosoma haema-
tobium. Diagnosis relies on serologic tests and/or stool
examination [24].
Other conditions such as malignancy (e.g. lung cancer)
and other infections (e.g. tuberculosis) are exceptionally
associated with eosinophilic lung disease.
Idiopathic eosinophilic lung diseases
Idiopathic acute eosinophilic pneumonia (IAEP) differs
from ICEP by the more rapid onset and the severity of its
clinical presentation. The time period between the onset
of symptoms and the diagnosis is usually inferior to 14
days [25,26]. In contrast to ICEP, an atopic background is
usually absent and there is no sex preponderance. Mean
age at presentation is about 30. Patients present with
cough and dyspnea, which is often severe and associated
with tachypnea. Chest pain of pleuritic character and fever
are frequently observed. Hypoxemic respiratory failure is
frequent at presentation, often requiring mechanical ven-
tilation [25,26]. On imaging, IAEP is characterized by dif-
fuse bilateral air-space or interstitial opacities without
peripheral predominance. Pleural effusion is frequent and
sometimes bilateral [25]. The white blood cell count
rarely points towards the diagnosis at presentation, with
the eosinophil count being lower than 500/mm3 in 2/3 of
the patients [25,26]. The BAL, however, is the key to the
diagnosis [25-27], showing an average percentage of eosi-
nophils of 40% in one series [25]. IAEP dramatically
improves with or without corticosteroid therapy but, in
contrast to ICEP, relapses are not described after tapering
or withdrawing treatment in IAEP.
Churg-Strauss syndrome (CSS) is a systemic eosinophilic
vasculitis which usually develops in patients with a long
history of atopic disease including asthma and, most
often, allergic rhinitis. Dramatic blood eosinophilia and
infiltration of a variety of tissues with eosinophils which
ensue, are eventually followed by a systemic vasculitis.
The latter affects many organs including the heart (heart
failure, acute coronary syndrome, pericarditis), the gastro-
intestinal tract (abdominal pain, gastrointestinal bleeding
or perforation), the skin (purpura, urticaria, nodules),
and the nervous system (mononeuritis multiplex, central
nervous system involvement). Pulmonary infiltrates, sim-
ilar to those described in ICEP, are observed in only half
of the cases at the time of diagnosis [28]. Antineutrophil
cytoplasmic autoantibodies (ANCA) with a perinuclear
pattern (p-ANCA) and an anti-myeloperoxydase specifi-
city are found in about 50% of patients with CSS [29]. As
already mentioned, it is likely that a continuum exists
between ICEP and CSS, at least in some patients.
Idiopathic hypereosinophilic syndrome (IHS), a rare and
heterogeneous disorder, has been defined by blood eosi-
nophilia greater than 1500/mm3 for more than 6 months,
and signs or symptoms of organ damage related to eosi-
nophilic infiltration [30]. Cardiac involvement including
mural thrombosis, endocardial fibrosis, which lead to
restrictive cardiomyopathy, is the most important compli-
cation of IHS and the major cause of morbidity and mor-
tality [31]. Pulmonary involvement is observed in 40% of
cases and is characterized by interstitial infiltrates on chest
imaging; pleural effusion is seen in 50% of affected
patients [32].
Cryptogenic organizing pneumonia shares many features
with ICEP with respect to clinical presentation and imag-
ing [33]. However, it is not associated with blood eosi-
nophilia and lymphocytes outnumber eosinophils in
BAL.
Treatment
Treatment of ICEP is based on oral corticosteroids. After
initiation of treatment, symptoms as well as blood eosi-
nophilia regress within a few hours and chest imaging
results normalize within a few days [3]. This dramatic
response to therapy has led to the consideration of corti-
costeroid challenge as a diagnostic test for ICEP [9]. There
is no consensus, however, on the doses or the duration of
the corticosteroid therapy. Most authors recommend ini-Orphanet Journal of Rare Diseases 2006, 1:11 http://www.OJRD.com/content/1/1/11
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tial doses of prednisone between 0.5 and 1 mg/kg/day
and a gradual tapering of the dose for a total treatment
duration of 6 to 12 months.
Long-term outcome
Although response to corticosteroid treatment is dramatic
and treatment always leads to complete resolution,
relapses of ICEP are observed in up to 50% of patients [3].
These relapses occur while tapering the dose of corticos-
teroids or after weaning. Relapses remain as responsive to
corticosteroids as the inaugural episode. Inhaled corticos-
teroids have been proposed in order to prevent relapses
[7]. This is supported by a lower rate of ICEP relapse in
asthmatics treated with inhaled corticosteroids [8].
The development of asthma in the follow-up of ICEP
patients is a common finding [8]. Up to one third of the
patients have asthma requiring long-term corticosteroid
therapy after a diagnosis of ICEP has been made, and
some patients develop a fixed obstructive pattern on pul-
monary function tests [8]. Overall, more than half of
patients affected by ICEP may require long-term oral cor-
ticosteroid therapy due to either multiple relapses or
severe asthma [8]. It is thus advisable to recommend
measures to prevent corticosteroid-induced osteoporosis
from the start of the treatment.
Unresolved questions
• Role of inhaled corticosteroids in the prevention of
relapses of ICEP.
• Possible overlap or continuum between ICEP and CSS.
• Doses and duration of corticosteroid treatment.
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